
Profitability, historical returns, and peer comparisons.
According to GH Research PLC’s latest financial reports and current stock price. The company's current ROE is -20.86%. This represents a change of 292.13% compared to the average of -5.32% of the last 4 quarters.
The mean historical ROE of GH Research PLC over the last ten years is -21.85%. The current -20.86% ROE has changed -4.53% with respect to the historical average. Over the past ten years (40 quarters), GHRS's ROE was at its highest in in the June 2022 quarter at 0.13%. The ROE was at its lowest in in the March 2021 quarter at -26.63%.
Average
-21.85%
Median
-16.25%
Minimum
-77.50%
Maximum
-3.32%
Discovering the peaks and valleys of GH Research PLC ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 170.76%
Maximum Annual ROE = -3.32%
Minimum Annual Increase = -89.84%
Minimum Annual ROE = -77.50%
| Year | ROE | Change |
|---|---|---|
| 2025 | -17.25% | -20.75% |
| 2024 | -21.77% | 33.96% |
| 2023 | -16.25% | 80.80% |
| 2022 | -8.99% | 170.76% |
| 2021 | -3.32% | -57.82% |
| 2020 | -7.87% | -89.84% |
The current ROE of GH Research PLC (GHRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-18.43%
5-year avg
-13.52%
10-year avg
-21.85%
GH Research PLC’s ROE is greater than Alto Neuroscience, Inc. (-46.46%), greater than LB Pharmaceuticals Inc Common Stock (-25.91%), greater than MapLight Therapeutics, Inc. (-63.84%), greater than Rapport Therapeutics, Inc. Common Stock (-34.00%), greater than Mind Medicine (MindMed) Inc. (-85.23%), greater than Neumora Therapeutics, Inc. Common Stock (-242.28%), less than Minerva Neurosciences, Inc. (250.02%), greater than Biohaven Ltd. (-2271.87%), greater than VistaGen Therapeutics, Inc. (-152.59%), greater than Seaport Therapeutics, Inc. Common Stock (-48.72%),
| Company | ROE | Market cap |
|---|---|---|
| -46.46% | $914.34M | |
| -25.91% | $1.32B | |
| -63.84% | $285.97M | |
| -34.00% | $1.24B | |
| -85.23% | $4.39B | |
| -242.28% | $106.35M | |
| 250.02% | $122.71M | |
| -2271.87% | $2.30B | |
| -152.59% | $8.18M | |
| -48.72% | $1.12B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GH Research PLC using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GH Research PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is GH Research PLC's ROE?
How is the ROE calculated for GH Research PLC (GHRS)?
What is the highest ROE for GH Research PLC (GHRS)?
What is the 3-year average ROE for GH Research PLC (GHRS)?
What is the 5-year average ROE for GH Research PLC (GHRS)?
How does the current ROE for GH Research PLC (GHRS) compare to its historical average?